← 治験一覧に戻る
局所進行性または転移性悪性固形腫瘍患者におけるエンフォルツマブベドチンの評価試験（EV-202）
基本情報
- NCT ID
- NCT04225117
- ステータス
- 実施中（募集終了）
- 試験のフェーズ
- 第2相
- 試験タイプ
- 介入
- 目標被験者数
- 329
- 治験依頼者名
- Astellas Pharma Inc
概要
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.
対象疾患
Locally Advanced or Metastatic Malignant Solid Tumors
介入
enfortumab vedotin(DRUG)
pembrolizumab(DRUG)